Merck and a plaintiff have paused a trial over alleged injuries from the HPV vaccine Gardasil, with ties to HHS Secretary ...
Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Merck and a plaintiff have paused a trial over potential Gardasil injuries, with ties to Health Secretary Robert F. Kennedy Jr. The trial resumes in September. Kennedy, involved in mass litigation ...
RFK Jr. played a lead role in building a case against Merck's HPV vaccine and could profit from the lawsuit alleging fraud, ...
They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...
Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, ...
Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.
Pause on Gardasil China sales from Feb to at least mid-2025 Keytruda beats, Gardasil misses Q4 sales estimates Merck pulls Gardasil's long-term sales target Shares tumble 11% in early trading ...